BSE filing, NSE: APLLTD. Summary written from the filing by ALFA Finder's alert engine.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹782.80
- Market cap
- ₹15,387 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 22.2×Sector 46.1×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Board Meeting Date
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.26 Cr
Alembic Pharmaceuticals' subsidiary, Alembic Global Holding SA, incorporated a new wholly-owned subsidiary, Alvesta Pharmaceuticals FZCO, in the UAE for Rs. 0.26 Crore.
- Value
- ₹0.26 Cr
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.23 Cr
Alembic Pharmaceuticals' wholly-owned subsidiary, Alembic Global Holding SA, incorporated a new step-down subsidiary, Alvesta Pharmaceuticals FZCO, in Dubai for AED 1 Lakh (approx. ₹0.23 Crore).
- Value
- ₹0.23 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP. This drug is therapeutically equivalent to the reference product Ciprodex Otic Suspension.
Alembic Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Other business update announcements
All →OnEMI Technology Solutions Business Update
OnEMI Technology Solutions (Kissht) disclosed its Key Performance Indicators for the quarter ended 30 September 2026. The KPIs, including those defined in its May 2026 prospectus, are published on the company website.
Hero MotoCorp Business Update
Hero MotoCorp updated its code of practices for fair disclosure of unpublished price-sensitive information, effective 28 October 2026. The revised code governs disclosure, spokespersons and analyst interactions.
Cybele Industries Business Update
Cybele Industries disclosed joint venture discussions with a third party, still at an initial stage. No agreement has been executed and no value is stated.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Vascon Engineers Business Update
Vascon Engineers awarded Neobridge Realty LLP a Rs.72 Crore shell and core work contract over 25 months. The contract is excluding GST and is described as ordinary course of business.
- Value
- ₹72.00 Cr
- Execution
- 25 months
Meesho Business Update
Meesho's Q2 FY27 shareholders' letter reports NMV up 23% YoY to ₹12,911 crore. Festive timing moved the Mega Blockbuster Sale into Q3.